David Melnick, MD

Dr. David Melnick is an Infectious Diseases clinician with 25 years of experience in anti-infective drug development. Prior positions have included VP, Clinical Development at AstraZeneca and Allergan, and Chief Medical Officer at Spero Therapeutics. Throughout his career, his focus has been on addressing antimicrobial resistance with novel antibiotics and novel dosing strategies. Successful antibiotic development programs have included meropenem, ceftaroline, and ceftazidime-avibactam.

He received his M.D. from Columbia University and completed his Residency in Internal Medicine at The New York Hospital-Cornell Medical Center. Following a Fellowship in Infectious Disease at Yale University, he has held faculty positions at the Boston University School of Medicine and NIAID. He is currently an independent consultant advising biotechnology companies on the design and delivery of innovative and efficient drug development programs.